


MICROBIOLOGY
IN
PHARMACEUTICAL
MANUFACTURING

SECOND EDITION
REVISED AND EXPANDED



Richard Prince
Editor

VOLUME 1

CONTENTS

	Introduction	xix
	<i>Richard Prince</i>	
I	Origins of Microbial Life	I
	<i>David R. Singleton, Kamlesh Jangid and William B. Whitman</i>	
	Introduction	1
	Molecular Chronometers	3
	Determining Phylogeny: Methodology Using 16S rRNA	7
	What Has 16S rRNA Told Us?	11
	The Origin of Life on Earth	17
	Additional Reading	19
	About the Authors	19
2	Epidemiological Principles and the Microbiology Laboratory	21
	<i>Lennox K. Archibald and William R. Jarvis</i>	
	Abstract	21
	Introduction	22
	Epidemiologic Methods	23
		iii

iv *Microbiology in Pharmaceutical Manufacturing — Volume I*

Infection, Colonization, and Disease	25
Infectious Disease Occurrence	28
Transmission, Reservoirs, and Spectrum of Disease	29
Incubation Period and Communicability	31
Integration of Epidemiology and Microbiology	32
Infectious Disease Surveillance	33
Epidemiology and Antimicrobial Resistance	39
Clinical Significance of Microorganisms and Laboratory Cost-Effectiveness	43
Outbreaks, Epidemics, and Epidemic Investigation	47
Investigating an Epidemic	48
The Role of Epidemiology and Microbiology in the Investigation of Outbreaks	52
Supplementary Laboratory Tests in Outbreak Investigations	54
Epidemiology and Bioterrorism	55
Prevention and Control	57
Epidemiology and Pseudoepidemics	59
Conclusion	61
References	62
About the Authors	72

3 **Taxonomy of Microorganisms** **75**

Shung-Chang Jong

Introduction	75
Taxonomy	76
Classification	77
Typification	78
Phenotypic Characteristics	80
Cultural and Morphological Characteristics	80
Physiological and Environmental Characteristics	80
Serological Characteristics	82
Chemical Characteristics	83
Genotypic Characteristics	83
DNA Base Composition	83
Mitochondrial DNA	84
DNA/DNA Homology	84
DNA/RNA Homology	85
Nucleic Acid Sequencing	85
Protein Sequencing	86
Types of Classification	86
Nomenclature	87
Scientific Names	87

Contents

v

	Authority	88
	Valid Publication	89
	Synonyms	90
	Identification	91
	Establishment of Pure Cultures	91
	Culture Collections	91
	Approaches to Identification	95
	Numerical Techniques	96
	Commercial Kits	96
	Conclusion	97
	Additional Reading	97
	About the Author	99
4	A Basic Primer on Pharmaceutical Microbiology	101
	<i>Hans van Doorne</i>	
	1 Introduction	101
	2 The Living World of Pharmaceutical Microbiology	103
	2.1 Characteristics of Life	103
	2.2 Phylogeny of the Living World	105
	Fungi	106
	Bacteria	107
	Viruses	111
	Prions	113
	3 Structure of the Bacterial Cell	114
	3.1 Flagella	114
	3.2 Pili and Fimbriae	115
	3.3 Capsule or Slime Layer	115
	3.4 Cell Wall Constituents	115
	Gram-positive Cell Wall	116
	Gram-negative Cell Wall (Outer Envelope)	116
	3.5 Cytoplasmic Membrane	116
	3.6 Cytoplasm	117
	3.7 Bacterial Endospores	117
	4 Microbial Growth and Survival	118
	4.1 Factors Affecting Growth and Survival	118
	4.1.1 Temperature	118
	4.1.2 Intrinsic Factors	118
	4.2 Fate of Microorganisms in Pharmaceutical Preparations	121
	5 Methods in Pharmaceutical Microbiology	123
	5.1 Nutrient Media	123
	5.2 Detection and Enumeration of Microorganisms	124
	5.2.1 Conventional Methods	125

	5.2.2 Alternative Methods	125
	5.3 Identification of Microorganisms	126
	5.4 Sources of Errors in Microbiological Quality Control	127
	5.4.1 Statistical Errors	128
	5.4.2 Selection of Incubation Conditions	130
	5.4.3 Sublethal Injury	131
	5.4.4 Inappropriate Neutralization of Antimicrobial Agents	133
	5.4.5 Adventitious Contamination	134
6	Industrial Applications of Pharmaceutical Microbiology	136
	6.1 Quantitative Microbiological Analysis	136
	6.1.1 Antibiotic Assays	136
	6.1.2 Vitamin Assay	139
	6.2 Production of Raw Materials and Active Substances	141
	6.2.1 Bioconversion	141
	6.2.2 Natural Secondary Metabolites	142
	6.2.3 Metabolites from Genetically Engineered Organisms	143
	6.2.4 Vaccines	146
7	Microbiological Hazards	147
	7.1 Pathogenicity	148
8	Description of Some Important Bacteria	150
	Staphylococcus	151
	Staphylococcus aureus	152
	Coagulase-negative Staphylococci	152
	Enterococcus	153
	Enterococcus faecalis	153
	Streptococcus	153
	Bifidobacterium	155
	Coryneform Bacteria	155
	Corynebacterium	155
	Propionibacterium	156
	Bacillus and Geobacillus	157
	Clostridium	157
	Clostridium tetani	159
	Clostridium botulinum	159
	Clostridium difficile	159
	Clostridium perfringens	159
	Pseudomonas and Related Genera	160
	Pseudomonas aeruginosa	160
	Burkholderia cepacia	161
	Ralstonia pickettii	161
	Brevundimonas diminuta	161

Contents

vii

Acinetobacter	162
Alcaligenes	162
Enterobacteriaceae	162
Escherichia coli	163
Other Enterobacteriaceae	163
Salmonella	163
Campylobacter	164
Legionella	164
Conclusions	164
References	165
About the Author	173
5	
Design, Commissioning and Validation of a Parenteral Manufacturing Facility	175
<i>Robert Del Ciello</i>	
Introduction	175
Project Team	176
Programming	179
Process Flow and Operational Flow Diagrams	180
Determination of Space Requirements	181
System Design Criteria	182
Architectural Treatments	183
Heating, Ventilation, and Air-Conditioning (HVAC)/	
Environmental System Design	187
Design Criteria	187
Pressurization	188
Temperature and Relative Humidity	189
Filtration	189
Dust Control	190
Air Handlers	190
Control and Control Devices	191
Utility Systems	191
Regulatory Issues	193
Commissioning, Qualification and Validation	194
Approach	195
Background	196
Methodology	196
Validation	199
Conclusion	200
References	200
About the Author	201

viii *Microbiology in Pharmaceutical Manufacturing — Volume I*

6	Process Capability and Product Specifications	203
	<i>Steven S. Kuwahara</i>	
	Specifications	205
	General	205
	Final Product Specifications	206
	Considerations from the Guidance Documents	207
	In-Process Specifications	209
	Purchasing Specifications	210
	Periodic Testing and Specifications (Periodic and Skip-lot Testing)	212
	Alternative Specifications and Testing Procedures	213
	Different Acceptance Criteria for the Same Specification	213
	Common Cause and Assignable Cause (Special Cause) Variations	215
	Records and Documentation	216
	Statistical Considerations	216
	Statistical Process Control	219
	Process Control	219
	Process Capability	220
	Control Charting	222
	Generic Control Charts	223
	Centerlines	224
	Number of Replicates (n) for Control Charts	224
	Control Limits	225
	A Warning	226
	Runs Rules and Processes That Are Out of Control	226
	How to Decide on the Number of Replicates (n)	227
	Calculation of n for an Average	227
	Number of Replicates (n) for Estimating Standard Deviations (s)	229
	Other Distributions	232
	Conclusion	232
	References	233
	About the Author	234
7	Microbiological Control Strategies During the Development of Pharmaceutical Products and Processes	237
	<i>M.J. Miller, M.E. Claerbout, R.A. DeMaio, J.K. Farrington, W.H. Johnston, D.K. Knoy, T.I. Nicas, M.J. Rubino, M.P. Stickelmeyer, K.L. Williams</i>	
	An Overview	237
	Concepts and Foundations of Pharmaceutical Contamination Control	237

Contents

ix

Microorganisms and Their Potential Impact on Pharmaceutical Preparations	238
Considerations During Development	241
Regulatory and Compendial Guidance	242
Hazard Analysis and Risk-Based Approaches to Microbial Control	243
Sources of Microbial Contamination and Methods of Control	244
Sources of Microbial Contamination	244
Raw Materials	244
Equipment	245
People	246
Components	246
Environment	246
Methods of Control for Microbial Contamination	247
Cleaning, Sanitization and Disinfection	247
Sterile Versus Non-Sterile Products	247
Filtration	248
Filtration of Oral Liquid Products	248
Pre-Filtration of Solutions to be Sterile Filtered	248
Sterile Filtration	249
Terminal Sterilization	250
Parametric Release	250
Water Activity	251
Considerations for the Microbial Control of Raw Materials	
Used in Drug Product Manufacturing	252
Natural Origin versus Synthetic Sources of Raw Materials	252
Active Pharmaceutical Ingredient (API)	253
Water	253
Gases	255
Considerations for the Control of Prions in Raw Materials	255
Considerations for the Microbial Control During the Manufacturing of API	256
Chemical Synthesis	256
APIs Expressed in Mammalian Cell Culture	258
Bioproducts Derived from Microbial Expression Systems	258
Viral Control in API Manufacturing	259
Considerations for Microbial Control During the Manufacture of Finished Product	261
Formulation Considerations	261
Active Pharmaceutical Ingredients	262
Excipients	262
Preservatives	262
pH	263

x *Microbiology in Pharmaceutical Manufacturing — Volume I*

Surface Tension	263
Osmolality	263
Redox Potential (Eh)	263
Storage Conditions	264
Process Considerations	264
Facilities, Equipment, Utilities, and Systems	264
Process Design	265
Process Definition	265
Special Considerations and Techniques	266
Process Qualification (PQ) Considerations	266
Primary Container/Closure Systems	267
Product Use	267
Considerations for Controlling Microbial Contamination	
Through the Use of Adequate Packaging and	
Container/Closure Systems	267
Container/Closure Integrity for Injectable Pharmaceutical	
Products	269
Vial/Stopper	269
Prefilled Syringes	269
Container/Closure Integrity for Bulk API	270
Maintenance of Container/Closure Integrity	270
Validation of Container/Closure Integrity	270
Microbial Ingress	270
Microbiological Aerosol Challenge	271
Dye Ingress	271
Headspace Vacuum or Pressure	271
Helium Leak Testing	271
Seal Force Monitoring	272
Measurement of Water Vapor Ingress	272
Electrical Conductivity	272
Considerations for Microbiological Quality Testing	272
Sampling Plans	273
Quality Attributes and Associated Tests	273
Sterility	273
Bacterial Endotoxin Testing	274
Bioburden (Microbial Limit) Testing and Tests for	
Specified Microorganisms	274
Antimicrobial Effectiveness Testing (AET)	275
Microbial Challenge Testing of Non-Preserved	
Products or Other Materials	276
Microbial Ingress Testing	276
Testing for Viruses, Mycoplasma, and Prions	276
Summary	277

Contents

xi

References	277
About the Authors	280
8 Microbiological Risk Assessment in Pharmaceutical Production Operations	283
<i>James Akers</i>	
Risk Analysis Methods	287
Sterile vs. Non-sterile Products	287
Methods for Implementing Microbial Risk Abatement	
Procedures for Non-sterile Products	288
Setting up a HACCP Plan for Non-sterile Pharmaceutical Risk Abatement	288
HACCP Prerequisites	290
Training	290
Establishing a HACCP Plan for a Production Process	291
Composition of a HACCP Team	291
Essential First Steps	291
HACCP Principle Tasks	292
Some Hazard Analysis Recommendations	293
Establishing Critical Control Points and Setting Control Levels	295
Risk Management and Monitoring	296
Risk Analysis in Aseptic Processing	298
Practical Means of Contamination Risk Abatement in Aseptic Processing	299
Conclusion	302
References	302
About the Author	304
9 Designing and Validating a Contamination Control Program	305
<i>Sandra A. Lowery and Maureen Mueller</i>	
Introduction	305
Contamination Control	307
Sources of Contamination	308
Extraneous Contamination: Microbial	308
Extraneous Contamination: Particulate	309
Extraneous Contamination: Chemical	309
The Human Factor	309
Trafficking	310
Surface Disinfection	310
Controlled Environments and Facility Design	311

xii *Microbiology in Pharmaceutical Manufacturing — Volume I*

Qualification of Classified Areas	314
Barrier Systems	315
Process Barrier	316
Equipment/Material/Personnel Barriers	316
Disinfection Program	317
Disinfectant Qualification Studies	320
Sterilization and Maintenance of Sterility	321
Operator Training and Qualification	324
Aseptic Technique	325
Interventions	325
Proper Cleanroom Behavior	326
Working in Unidirectional Airflow	327
cGMPs of Contamination Control	328
Aseptic Operator Qualification Curriculum	328
Controlled Area and Aseptic Gowning	330
Controlled Area Gowning	330
Aseptic Gowning	330
Aseptic Gowning Qualification	331
Process Simulation Studies (Media Fills)	333
Introduction	333
Sterile Bulk Process Simulations	335
Principles of Challenge: Aseptic Filling and/or Bulk	
Processing	336
Study Design	336
Use of a Matrix Approach	337
Frequency of Challenge	338
Choice of Media	340
Oxygen Availability	341
Fill Volume	341
Personnel Intervention	342
Duration and Yield	345
Worse-Case Conditions (“Standard” and “Defined”)	347
Documentation	349
Unit Inspection	350
Unit Incubation Requirements	351
Unit Accountability and Reconciliation	353
Acceptance Criteria	353
Investigations	355
Lyphilization Simulation	357
Additional Measurement Programs: Environmental and	
Personnel Monitoring	358
Sterility Testing	362
Bioburden and Endotoxin Burden Program	363

Contents

xiii

	Data Trending and Analysis	365
	Correlation of Assessments/Annual Product Reviews	366
	Conclusion	366
	References	367
	Additional Reading	368
	About the Authors	369
10	Microbiological Control in Fermentation, Cell Culture and Downstream Purification Processes	371
	<i>Trevor Deeks</i>	
	Introduction	371
	Sources of Microbial Contamination in Biological Processes	373
	Microbial Fermentation and Mammalian Cell Culture	378
	Harvest and Extraction	383
	Downstream Purification of Proteins and Other Large Molecules	385
	Microbiological Control and Storage of Buffers	386
	Sanitisation and Storage of Resins and Membranes	387
	Endotoxin Sources and Control	388
	Final Filtration and Filling	388
	Control Strategies	389
	Live Vaccines	390
	Other Biological Processes	396
	Summary	398
	References	398
	About the Author	399
11	Sterilization Process Validation	401
	<i>James Agalloco</i>	
	Introduction	401
	Validation Supportive Activities	402
	Equipment Qualification (EQ)	404
	Installation Qualification	404
	Operational Qualification	405
	Validation Maintenance	406
	Sterilization Process Development	407
	Performance Qualification	407
	Introduction to Sterilization	408
	Steam Sterilization	411
	Component Mapping	416
	Determination of Sterilization Process Objective	417
	Empty Chamber Studies	417

xiv *Microbiology in Pharmaceutical Manufacturing — Volume I*

Load Definition	418
Temperature Penetration/Biological Indicator Studies	420
Validation using the Overkill Method	421
Validation using the BB/BI Method	422
Additional Perspectives on Terminal Sterilization	422
Sterilization-in-Place (SIP)	423
Dry Heat Sterilization and Depyrogenation	424
Component Mapping for Ovens and Tunnels	426
Load Mapping for Ovens	426
Empty Oven Temperature Distribution	427
Loaded Chamber Studies in Ovens	427
Depyrogenation in Dry Heat Tunnels	427
Empty Tunnel Temperature Distribution	428
Loaded Tunnel Heat Penetration and Depyrogenation	
Challenge	429
Gas/Vapor Sterilization	430
Gas Sterilization	431
Vapor Sterilization	432
H ₂ O ₂ Sterilization	433
Peracetic Acid Decontamination	433
Validation of Gas/Vapor Sterilization	433
Sterilization by Irradiation	434
Gamma Sterilization	434
E-Beam and X-ray Sterilization	435
Common and Key Elements of Radiation Sterilization	435
Materials Compatibility	435
Establishing the Dose	435
Dose Confirmation	437
Validation Requirements	437
Routine Process Control	437
Equivalence in Validation	438
Sterilizer Equivalence	438
Load Equivalence	438
Container Equivalence	438
Formulation Equivalence	439
Product Equivalence	439
Multiple Equivalence	439
Time Equivalence	439
Equivalence for Sterilization Processes	439
Establishing Equivalence	440
Biological Indicators	440
Validation Maintenance/Change Control/Re-validation	443
Conclusion	444




Appendix I: Steam Sterilization Overkill Acceptance	
Criteria	444
References	445
About the Author	449
12 Sterilizing Filtration of Liquids	451
<i>Richard V. Levy</i>	
Abstract	451
Background	451
Sterile Filtration in the 1990s	452
United States: Emphasis on Filter Validation	453
Europe: Terminal Sterilization, Bioburden Control, and Redundant Filtration	454
Reevaluation of 0.22 μm Microbial-Retention Standards	455
Filter Ratings: A Manufacturer's Qualification Quandary	456
Filter User's Quandary: How do I Choose and Validate a Sterilizing-Grade Filter?	457
When in Doubt, Follow the Published Regulatory Guidances	457
Industry Provides Important Guidance	458
The Classic Dilemma: Has the Filtration Been Successful?	459
Validation of Other Critical Parameters of Filters	459
Filter Compatibility	459
Filter Leachables and Extractables	459
Membrane Filter Assemblies: Polymeric Cartridges/ Stainless Steel Housings and Newer Polymeric Capsules	460
Filter Integrity	460
Sterile Filtration in the 21st Century	461
Recommendations for a Better Understanding and Mitigation of the Risk of Using Sterilizing-Grade Filters in Aseptic Processing	461
Evaluate the Mechanisms in Microbial Retention in Sterilizing-Grade Filters	461
Conduct Bioburden Studies	461
Conduct Generic Bioburden Risk Evaluation	462
Conduct Specific Filtration "Failure" Studies	462
Eliminate Pore Size Ratings	462
Acknowledgements	463
References	463
About the Author	466

xvi	<i>Microbiology in Pharmaceutical Manufacturing — Volume I</i>	
13	Cleaning Validation Program	469
	<i>William E. Hall</i>	
	Introduction	469
	Definitions	470
	Potential Sources and Types of Product and Equipment Contamination	473
	Risk Assessment as a Preliminary Event for Cleaning Validation	473
	Matrix, Product Grouping, and Identifying Worse Case Products as an Approach to Cleaning Validation (for Chemical Residues)	474
	Types of Cleaning	476
	Importance of Validation of the Cleaning and Sanitization Processes	477
	Cleaning Procedures	478
	Controls Required for Validated Cleaning and Sanitizing Procedures	479
	Requirements for Dedicated Equipment	479
	Monitoring of the Cleaning and Sanitization Processes	480
	Criteria for Revalidation of Cleaning and Sanitization Procedures	480
	Documentation Requirements	480
	Sampling Methods and Locations	482
	Analytical Methods	487
	Limits and Acceptance Criteria — General Considerations	489
	Limits for Chemical Residues	490
	Limits for Microbiological Residues	493
	Conclusion	494
	References	495
	About the Author	498
14	Pharmaceutical Water	499
	<i>T.C. Soli</i>	
	Introduction	499
	Types of Water	500
	Microbial Growth in High Purity Water Systems	516
	Impact of Where Biofilm Grows	519
	Impact of Surface Properties on Biofilm Development	526
	Biofilm Control	527
	Tenet #1 — Use an Effective Sanitizing Agent	528
	Tenet #2 — Use Effective Sanitization Procedures	528
	Tenet #3 — Sanitize Frequently	529
	Tenet #4 — Minimize Re-colonization	530
	Sanitizer Options and How They Work	531

*Contents***xvii**

Hot Water	531
Steam	532
Ozone	533
Hydrogen Peroxide	535
Peracetic Acid	537
Hydrogen Peroxide + Peracetic Acid Mixes	537
Chlorine and Hypochlorite	538
Chlorine Dioxide	539
Formaldehyde	539
Glutaraldehyde	540
Cationic Detergents	540
Caustic	540
Bromine and Iodine	540
Biofilm Enumeration Approaches	541
Impact of Microbial Monitoring Data Timeliness	543
In/On-line Enumeration Approaches	544
Off-line Enumeration Approaches	546
Direct Microscopic Counting Techniques	546
Correlates to Microbial Counts	547
Early Colony Detection Approaches	549
Conventional Full-Term Cultural Approaches	551
Plate Count Approach	552
Sample Volume and Colony Counts	553
Growth Medium Options	553
Incubation Temperature and Time Options	557
Validating the Suitability of Your Water Test Method	558
Microbial Identification and Detecting Specific Objectionables	563
Purposes of Microbial Enumeration and Sampling	568
Trend Analysis	570
Water System Validation and its Life Cycle	576
Conclusions	582
References	583
About the Author	586

Index**587**



INTRODUCTION

In the 1980s, we witnessed the beginning of the AIDS pandemic. It remains out of control in parts of the developing world. In the first decade of this century, we saw indicators of an avian influenza pandemic possibly one day ravaging humanity. What will happen in the next decade or two? What impact will climactic variability, whether “natural” or human-derived — have on microorganisms that cohabit our planet? Will it subtly change microbial ecosystems in a manner that will impinge upon eukaryotic ecosystems, including our own? Will the march of biotechnology soon lead to the plausible use of “designer genomes” that will benefit humans? And, if so, how will the community of microorganisms respond? I would guess in a way that reestablishes some degree of inter-species stability to neutralize the impact of human intervention. Regardless, we seem fated to continue to engineer new industrial approaches — including the recent, remarkable advances in creating synthetic microorganisms — intended to either safeguard our species from the ever-present danger of microorganisms or to leverage microorganisms themselves for some other useful benefit to humanity. We humans are endowed with a purpose. We now have the molecular biological methods to change the natural world to serve our purpose. A basic respect for microorganisms and the field of microbiology is thus in order!

The pharmaceutical industry exists to discover, develop, manufacture and distribute diagnostic and therapeutic products (drug; biologics) that will protect and advance human health. Some of these drugs (antibiotics) are designed to kill pathogenic microorganisms, some are designed to prevent disease in the first place

(vaccines) while yet others are intended to improve some type of biological performance. All drugs, biologics and allied products must be manufactured properly so that they themselves are not the carriers of disease and death. Microbes seemingly lurk everywhere. So, our task as an industry is to design, develop and implement quality systems that will be used in a manufacturing setting to help ensure that product batches are consistently made to all predefined quality attributes and specifications. But quality of course is more than just meeting specifications; it is attitudinal. Quality (as a discipline, as a field) is about — or should be about — identifying new, more sophisticated ways to maintaining and augmenting our assurance of the quality of the products that are commercially distributed. This is not an easy task given the scale and variability expressed in microbiological systems as well as the variability experienced in the systems used to manufacture, test and distribute such products. And even if we could outwit microorganisms (through technology, in particular) in our ability to consistently provide safe and efficacious products of highest possible quality, it can become somewhat moot given the uneven compliance practices of humans to dispense and administer such products at home. Microbes are like slippery eels that we seek to temporarily grab but we can't in fact hold on to for very long. We try to control them, even to conquer them, but for every new drug or biologic that satisfies an unmet clinical need, there is, as well, the steady sting of microbial mutation, of microbial resistance, and of primitive, prokaryotic defiance. Microbes, then, are friend and foe, a formidable intellectual and enduring professional challenge for the scientist, the ethicist and the philosopher.

In the first edition of this book, published in 2001, the reader was advised to think of microbiology in a comprehensive and systematic way. That book was very well received and argued the need for a second edition, which is hereby presented. If there is a message in this edition, it is this: Our health is a function of many variables, some within our control (e.g., living practices) and some beyond (e.g., our genetic make-up), and our ability to maintain or improve our health rests upon our humility to appreciate the fragility and variability of life, the difficulty in changing our ways, and the insidious, invisible, ubiquitous role played by microorganisms. We must be vigilant, but we must also be sensible in the things that we can do to meaningfully improve our quality of life. Our noble pursuit is to try and raise the bar on human longevity and wellness. Somewhere in that quest, we intersect with microorganisms, charged with their own ancient, ambivalent mission. We will need to summon all of our creative talents and wisdom to strike the proper balance between the conflicting human traits of hegemony and humility.

The second edition is largely modeled on the first edition. Many of the authors who contributed chapters in the first edition have updated their respective chapters for this edition. Some authors appear for the first time in this text. All of them are subject-matter experts in their respective fields, they are found throughout the regulated world, and all of them provide content that will be of practical benefit to the pharmaceutical and biologics industry, and all of its allied fields.

Volume 1 covers Chapters 1–14

- Phylogeny
- Epidemiology
- Taxonomy
- Industrial Microbiological Primer
- Parenteral Facility Engineering
- Process Capability and Product Specifications
- Control Strategies during Product Development
- Risk Assessment in Production Operations
- Designing and Validating a Contamination Control Program
- Control Strategies for Biological Processes
- Sterilization Process Validation
- Sterilizing Filtration of Liquids
- Cleaning Validation
- Water Microbiology.

Volume 2 covers Chapters 15–30

- Science of Particulates
- Environmental Monitoring
- Disinfectants and Other Chemical Germicides
- Training of Aseptic Processing Personnel
- Comparison of Global Compendial Methods
- Rapid Microbiological Technologies and Methods (two chapters)
- Bacterial Endotoxins Testing
- Microbial Limits Testing
- Stability Program
- Handling and Management of Deviations
- Modern Quality Systems
- Regulatory Stewardship: Global Regulatory Dossier
- Internet and Microbiology
- Expert Opinion on Aseptic Processing.

The goal of this book is to provide updated and expanded microbiological information for the benefit of a global audience of stakeholders. It is sincerely hoped that each reader will find some content that will aid in formulating keener questions as well as finding smarter solutions, in a way that brings credit to all.

Richard Prince
Short Hills, New Jersey USA
December 2007

